Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

• Alan L. Ho ,

  * E-mail: hoa@mskcc.org

  Affiliations Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, Department of Medicine, Weill Medical College of Cornell University, Ithaca, New York, United States of America

  ⨯
• Elgilda Musi,

  Affiliation Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Grazia Ambrosini,

  Affiliation Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Jayasree S. Nair,

  Affiliation Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Shyamprasad Deraje Vasudeva,

  Affiliation Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Elisa de Stanchina,

  Affiliation Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Gary K. Schwartz

  Affiliations Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, Department of Medicine, Weill Medical College of Cornell University, Ithaca, New York, United States of America

  ⨯